The principle of peptide cancer vaccines is based on selecting peptide sequences from either tumor-specific or tumor-associated antigens containing T cell epitopes, which are recognized by CD8+ and/or CD4+ T cells in a population with matching HLA haplotypes. The gene discussed is CD4; the disease is neoplasm.